Here are the 10-K annual reports from Contineum Therapeutics, Inc. (CTNM) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CTNM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTNM filings page.
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small‑molecule therapies for neuroscience, inflammation and immunology diseases. Its lead wholly owned candidate, PIPE‑791, is an LPA1 receptor antagonist in a global Phase 2 trial for idiopathic pulmonary fibrosis and a Phase 1b study for chronic osteoarthritic and low back pain, with top‑line pain data expected in the second quarter of 2026.
The company’s second key asset, PIPE‑307, a selective M1 receptor antagonist, is partnered with Johnson & Johnson under an exclusive global license that included a $50.0 million upfront payment, potential milestones of about $1.0 billion and tiered royalties. A Phase 2 proof‑of‑concept trial in major depressive disorder is underway, while a Phase 2 trial in relapsing‑remitting multiple sclerosis showed acceptable safety but did not meet primary or secondary efficacy endpoints.
Contineum reports high dependency on PIPE‑791 and PIPE‑307, notes significant expected increases in operating expenses, and may require substantial additional capital. As of February 27, 2026, it had 37,336,036 total shares outstanding, including 32,673,536 Class A and 4,662,500 Class B shares.